Abstract 1235
Background
Uveal Melanoma (UVM) is the most common ocular malignancy. Many mutations were identified in affected patients defining genetic predisposition syndromes. Previous studies discussed separately the incidence of single or second primary ocular melanomas. However, understanding the genetic background, and relation to other tumors requires further investigation for defining the UVM subgroups, their shared developmental and, hence, the targeting mechanisms.
Methods
We used Surveillance Epidemiology and End Results program of the National Cancer Institute, United States, to review patients diagnosed with UVM, either as single primary or combined with other malignancies, between 1973 and 2015. We have calculated standardized incidence ratios (SIR) and measured risk in the form of Observed/Expected ratios (O/E) and Hazard Ratios (HR).
Results
We have identified 7,386 patients diagnosed with single primary UVM, besides 646 with UVM followed by another malignancy and 437 patients diagnosed with a primary UVM after other malignancies. SIR of developing another malignancy following UVM was significant and increased most within the first 5 years following UVM following choroid uveal melanoma (1.198, 95%CI=1.056-1.353). The risk of developing melanomas of the skin, thyroid cancers, and kidney cancers, increased significantly within the first 5 years following UVM, with SIRs (3.763, 95%CI=2.539-5.372), (3.158, 95%CI=1.270-6.506), and (2.618, 95%CI=1.465-4.317), respectively. SIR of developing a second UVM following another malignancy was significant between the 5th and 10th years following the first cancer diagnosis (O/E=1.204, 95% CI = 1.007-1.428), where the increase of UVM risk was highest among patients with primary prostate cancer (1.404, 95%CI=1.024-1.878) or leukemia (2.915, 95%CI=1.070-6.345). Cox models did not show a significant difference between the overall survival of single UVM and second UVM, but females showed better overall survival outcomes. In addition, Ciliary body tumors, and dark-skinned people were associated with worse survival outcomes.
Conclusions
The three groups of uveal melanoma showed different behaviors that may represent diverse underlying developmental mechanisms.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5218 - Elevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
Presenter: Bram De Laere
Session: Poster Display session 3
Resources:
Abstract
2452 - High proportion of multiple KRAS mutations in circulating tumor DNA and tumor tissue of pancreatic ductal adenocarcinoma
Presenter: Min Kyeong Kim
Session: Poster Display session 3
Resources:
Abstract
3328 - Biological difference of tumor mutational burden (TMB) and microsatellite instability (MSI) status in patients (pts) with somatic vs. germline BRCA1/2-mutated advanced gastrointestinal (GI) cancers using cell-free DNA (cfDNA) sequencing analysis in the GOZILA study
Presenter: Yasuyuki Kawamoto
Session: Poster Display session 3
Resources:
Abstract
3022 - Cell-Free DNA to Detect Focal Versus Non-Focal MET Amplification in Metastatic Colorectal Cancer Patients: Combined Analysis from Japan and the United States
Presenter: Mishima Saori
Session: Poster Display session 3
Resources:
Abstract
2833 - Presence of circulating tumor DNA in surgically resected renal cell carcinoma is associated with advanced disease and poor patient prognosis
Presenter: Andres Correa
Session: Poster Display session 3
Resources:
Abstract
1376 - Combined genomic and epigenomic assessment of cell-free circulating tumor DNA (cfDNA) for cancer diagnosis and recurrence-risk assessment in early-stage lung cancer
Presenter: Junghee Lee
Session: Poster Display session 3
Resources:
Abstract
4050 - DEMo: a prospective evaluation of a prognostic clinico-molecular composite score in NSCLC patients treated with immunotherapy.
Presenter: Arsela Prelaj
Session: Poster Display session 3
Resources:
Abstract
4727 - Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)
Presenter: Cindy Yang
Session: Poster Display session 3
Resources:
Abstract
3662 - Dynamic changes in whole-genome cell-free DNA (cfDNA) to identify disease progression prior to imaging in advanced solid tumors
Presenter: Andrew Davis
Session: Poster Display session 3
Resources:
Abstract
3817 - Evaluation of Microsatellite Instability Testing Through cell-free DNA sequencing
Presenter: Shile Zhang
Session: Poster Display session 3
Resources:
Abstract